HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Testing Minimal Residual Disease in NonSecretory Myeloma Patients with clonoSEQ
Testing Minimal Residual Disease in NonSecretory Myeloma Patients with clonoSEQ image
Non-Secretory Myeloma Community Chapter
event Aug 23, 2022 / 01:00PM - 02:00PM EDT

Event Description

Meet with us this month to discuss minimal residual disease testing and how it can be beneficial to nonsecretory myeloma patient care.

Schedule & Agenda

The panelist Vicki Jones
Introduction
01:00PM
Vicki Jones
Vicki introduces the agenda of the event and featured speaker Mark Schliekelman.
The panelist Mark Schliekelman
Presentation
01:05PM
Mark Schliekelman
Mark discusses minimal residual disease testing for Non-Secretory patients.
The panelist Audience
Questions and Answers
01:35PM
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Vicki Jones
Vicki Jones

Vicki has been fighting Myeloma since 2004 when she was diagnosed with stage 2 Myeloma and began aggressive chemotherapy. After a stem cell transplant in 2007 from which she obtained a very good partial response, Vicki has been on just about every drug regimen available. Every drug has worked well but, of course, nothing works forever. Recently after being IGA lambda for over 17 years, Vicki became a non-secretor and now leads Healthtree’s non secretory community group. Throughout her myeloma journey, Vicki has gratefully maintained an excellent quality of life and now finds joy in helping others diagnosed with Myeloma.

Read Bio
The panelist Mark Schliekelman
Mark Schliekelman

Experienced Medical Science Liaison with with deep understanding of Oncology and Pharmaceuticals . Skilled in Scientific Review, Molecular Biology, Biotechnology, Cell Culture, and Scientific Writing. Strong research professional with a Doctor of Philosophy (Ph.D.) focused in Genetics and Molecular Biology from UNC Chapel Hill. I see my role: As identifying engaging and maintaining relationships with Key Opinion Leaders. To be a collaborative and supportive partner with business and research professionals. As a Medical Affairs Facilitator and subject matter expert with a demonstrated ability effectively communicate. To provide information that is clear, concise and clinically relevant. To ask provocative questions that challenge current assumptions. Provide thoughtful answers to queries and concerns. Give peer level support in ensuring well-run research and trials. I consider myself to be a person of integrity; principled, diplomatic, calm, thoughtful and reflective. I have a deep understanding of oncology and am able to go toe to toe with Key Opinion Leaders in an engaging scientific exchange.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube